Holen Sie sich die Stockscreener-App
248.80
0.02%
-0.02
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference - finance.yahoo.com
ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments - TradingView
2 Dividend Stocks Built to Hold Up When Markets Don't - The Motley Fool
AbbVie stock slips as Q2 revenue rises 10.2 percent - AD HOC NEWS
AbbVie issues US$10 billion to fund Apogee acquisition - fi-desk.com
AbbVie stock heads into the open after a 2.99 percent drop - AD HOC NEWS
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note - finance.yahoo.com
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
Why Did AbbVie (NYSE:ABBV) Just Close Its Biggest Deal In Years? - Kalkine Media
Is AbbVie Stock Too Reliant On Skyrizi? - Trefis
AbbVie Inc. stock edges lower as investors weigh strong earnings and higher analyst targets - AD HOC NEWS
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282 - Moomoo
BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $282 - Moomoo
BofA raises Abbvie stock price target on Apogee deal close By Investing.com - Investing.com India
BofA raises Abbvie stock price target on Apogee deal close - Investing.com
AbbVie’s Next Skyrizi Catalyst Lands This Fall. Here’s What’s at Stake for the Stock - TIKR.com
AbbVie Inc. (ABBV) Stock Analysis: Exploring Growth Potential Amidst A Solid 7.85% Upside - DirectorsTalk Interviews
What Does Friday’s Close Mean for AbbVie (NYSE:ABBV) and NYSE? - Kalkine Media
Mary Kuriakose Starts New Oncology Leadership Role at AbbVie - Oncodaily
AbbVie Inc. stock holds near highs as Apogee deal and guidance support sentiment - AD HOC NEWS
Key deals this week: Flex, Nvidia, AbbVie and more (VRT:NYSE) - Seeking Alpha
Michael Henderson: A New Chapter Begins for Apogee Therapeutics With AbbVie - Oncodaily
Scotiabank Remains a Buy on AbbVie (ABBV) - The Globe and Mail
AbbVie-allied ADARx aims to go public with 3 drugs in the clinic - Endpoints News
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Trailing rivals, AbbVie scores win with dual-acting myeloma drug - BioPharma Dive
AbbVie Inc. stock gains on Apogee deal and reaffirmed 2026 guidance - ad-hoc-news.de
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study - Yahoo Finance
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing? - finance.yahoo.com
AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma - finance.yahoo.com
AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis) - Seeking Alpha
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story - finance.yahoo.com
AbbVie-owned Apogee Therapeutics (APGE) pulls unsold stock - Stock Titan
CFO of Apogee Therapeutics (APGE) gives up last shares in AbbVie buyout - Stock Titan
AbbVie's Etentamig Delivers 74% Response Rate in Pivotal Cancer Trial - finance.yahoo.com
AbbVie’s Etentamig Suits Community Setting With Monthly Dosing, Low Toxicity - insights.citeline.com
AbbVie Completes $10.9 Billion Acquisition Of Apogee Therapeutics - Pulse 2.0
Top Analyst Reports for Amazon, AbbVie & Alibaba - Yahoo Finance
AbbVie Touts Positive Data For Multiple Myeloma Drug - finance.yahoo.com
AbbVie Completes $10.9 Billion Apogee Acquisition, Adds Zumilokibart to AD Pipeline - Dermatology Times
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care? - Trefis
AbbVie's etentamig hits dual primary endpoints in Phase III relapsed/refractory multiple myeloma trial - The Pharma Letter
AbbVie's blood cancer therapy lowers disease progression, death risk in trial - Reuters
ABBV Looks 18.1% Overvalued on GF Value™ Amid Dividend Strength - GuruFocus
AbbVie Completes Acquisition of Apogee Therapeutics - Investing News Network
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma - Investing News Network
AbbVie could take BiTE of Tecvayli market share on Phase III MM win - finance.yahoo.com
ABBV Looks 19.1% Overvalued on GF Value™ as Dividend Sustainabil - GuruFocus
AbbVie posts trial win for multiple myeloma drug (ABBV) - Seeking Alpha
AbbVie seals $11B acquisition of Apogee Therapeutics (ABBV:NYSE) - Seeking Alpha
AbbVie will stream its healthcare talk live Sept. 15 - Stock Titan
AbbVie (ABBV) Stock Looks Fully Priced Despite A 43% Fair Value Gap - Yahoo Finance
Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care - AbbVie News Center
AbbVie Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings - PR Newswire
Global pharma companies that have publicly announced Trump drug pricing agreements - reuters.com
AbbVie’s Sept. 9 healthcare talk will stream live and stay online - Stock Titan
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):